Windlas BiotechNSE:WINDLAS +1.24%89 Shareholder Yield % is 0.25% as of Mar. 2026, which is 69% below its 10-year median of 0.81. GuruFocus rates NSE:WINDLAS with a GF Score™ of 89/100 and a GF Value™ of ₹934.52 (Fairly Valued). The stock has 1 warning sign investors should review. Among 970 Drug Manufacturers companies, Windlas Biotech ranks worse than 50.82% on this metric.
Shareholder Yield % is how much money shareholders receive from a company that is in the form of cash dividends, net stock repurchases, and debt reduction. It is a measure of shareholder return.
As of today, Windlas Biotech's Shareholder Yield % was 0.25%.
Shareholder Yield % is how much money shareholders receive from a company that is in the form of cash dividends, net stock repurchases, and debt reduction. The term was coined by William W. Priest of Epoch Investment Partners in a paper in 2005 entitled The Case for Shareholder Yield as a Dominant Driver of Future Equity Returns. William Priest indicated that "shareholder yield is a term that we came up with to reflect the various ways dividends can be paid to owners of a business in a publicly-traded company."
Dividend Yield % shows how much a company pays out in dividends each year relative to its stock price, which is most obvious form of shareholder return.
Buyback Yield % is the net repurchase of shares outstanding over the market capital of the company. Shares repurchases also increase shareholder value by returning the money back to shareholders.
Net Debt Paydown Yield % is the change in average of four quarters of company's total debt over a company's market cap. Assuming the total value of a company remains that same, shareholder value is increased as debt is reduced.
Windlas Biotech Shareholder Yield % Related Terms
Windlas Biotech Shareholder Yield % Historical Data
* Premium members only.
The historical data trend for Windlas Biotech's Shareholder Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NSE:WINDLAS vs ZTS, UTHR: Shareholder Yield % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Windlas Biotech's Shareholder Yield %, along with its competitors' market caps and Shareholder Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Windlas Biotech Shareholder Yield % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Windlas Biotech's Shareholder Yield % distribution charts can be found below:
* The bar in red indicates where Windlas Biotech's Shareholder Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* All the data are calculated by TTM values. Note that if a companies is traded in several exchanges, then we calculate the company level data for Shareholder Yield % using the primary share class stock data. The calculation result in definition page is for demonstration purpose only, and it's showing the share class level data. Therefore, the numbers in the calculation may differ from elsewhere if the stock is not a primary share.
Windlas Biotech (NSE:WINDLAS) has a Shareholder Yield % of 0.25% as of Mar. 2026. Shareholder Yield is how much money shareholders receive from a company that is in the form of cash dividends, net stock repurchases, and debt reduction. View historical data on Windlas Biotech and its competitors. This is 69% below median its historical median of 0.81. According to the industry distribution chart, Windlas Biotech ranks #493 out of 970 companies in the Drug Manufacturers industry, placing it in the top 50.8%.
Is Windlas Biotech's Shareholder Yield % too high?
Windlas Biotech's current Shareholder Yield % of 0.25% is 69% below median its 10-year median of 0.81. The Drug Manufacturers industry median Shareholder Yield % is 0.34. Windlas Biotech's value of 0.25% is 25.4% below this industry median. Based on the distribution chart, Windlas Biotech ranks #493 out of 970 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Windlas Biotech has a GF Score™ of 89/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Windlas Biotech's Shareholder Yield % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Windlas Biotech ranks #493 out of 970 companies for Shareholder Yield %. This places Windlas Biotech in the lower half of its industry. The industry median Shareholder Yield % is 0.34. Windlas Biotech's value of 0.25% is 25.4% below this benchmark. While the company's 10-year median is 0.81 vs. the industry median of 0.34, Windlas Biotech has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Shareholder Yield % for a Drug Manufacturers company?
The median Shareholder Yield % among Drug Manufacturers companies is 0.34, based on 970 companies in the industry. Companies in the top quartile (top 25%) have a Shareholder Yield % significantly above this median, while those in the bottom quartile fall well below. However, Shareholder Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Windlas Biotech's current Shareholder Yield % of 0.25% is 25.4% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Shareholder Yield % mean?
A high Shareholder Yield % can signal that a stock is expensive relative to its fundamentals. Shareholder Yield is how much money shareholders receive from a company that is in the form of cash dividends, net stock repurchases, and debt reduction. View historical data on Windlas Biotech and its competitors. For the Drug Manufacturers industry, the median Shareholder Yield % is 0.34 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Windlas Biotech's current Shareholder Yield % is 0.25%, which is 69% below median its own 10-year median of 0.81. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Windlas Biotech stock overvalued right now?
Based on GuruFocus' analysis, Windlas Biotech (NSE:WINDLAS) is currently considered Fairly Valued. The stock's GF Value™ is ₹934.52, compared to a current price of ₹871.90 — trading 6.7% below its estimated fair value. The current Shareholder Yield % is 0.25%, which is 69% below median its 10-year median of 0.81 and 25.4% below the Drug Manufacturers industry median of 0.34. Windlas Biotech's overall GF Score™ is 89/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Shareholder Yield % calculated?
Shareholder Yield % is calculated from a company's financial statements. For Windlas Biotech (NSE:WINDLAS), the current Shareholder Yield % is 0.25% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Windlas Biotech (NSE:WINDLAS) Overvalued in 2026?
Based on GuruFocus' analysis, Windlas Biotech stock appears to be undervalued.
The current stock price of ₹871.90 is trading 6.7% below its estimated GF Value™ of ₹934.52.
GuruFocus considers Windlas Biotech to be Fairly Valued.
Key valuation signals for NSE:WINDLAS:
Shareholder Yield %: 0.25% (69% below median its 10-year median of 0.81)
GF Value™: ₹934.52 vs. price of ₹871.90 (6.7% below fair value)
Industry Position: 25.4% below the Drug Manufacturers median (#493 of 970)
No single metric tells the full story. See the NSE:WINDLAS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Windlas Biotech Ltd is a pharmaceutical formulation contract development and manufacturing organization. The company offers a range of CDMO services from product discovery to product development, licensing, and commercial manufacturing of generic products including complex generics.
89GF Score
Get the complete analysis for NSE:WINDLAS
Shareholder Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:WINDLAS has been successfully added to your 
